Rosopatamab Biosimilar - Research Grade

Human

PMSA

>1mg/ml

Human IgG1 (E356D/M358L)-kappa

Capromab Biosimilar - Research Grade (ICH5427), Pelgifatamab Biosimilar - Research Grade (ICH5766)

https://www.imgt.org/mAb-DB/

ICH3002

Q04609

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-PSMA antibody rosopatamab, built around prostate-specific membrane antigen (PSMA/FOLH1, UniProt Q04609). It is supplied as a research-grade reagent for research use only and is not the clinical drug; it is not intended for human or veterinary use. The molecule is a full-length human IgG1-kappa carrying engineered heavy-chain substitutions (E356D/M358L) in the Fc region, provided in an unconjugated format without any radiolabel, toxin, or linker. Because the originator is developed as a radio-antibody conjugate scaffold, the unconjugated analog is well suited to in-vitro and preclinical work where a defined, consistent anti-PSMA binder is needed: antigen-binding and epitope-competition assays, PSMA-positive versus PSMA-negative cell binding and internalization studies, flow cytometry and immunocytochemistry, isotype/targeting controls, and as a starting reagent for conjugation, ADC, or radioconjugate development. It is available with low endotoxin (research grade below 1 EU/mg, ultra-low below 0.5 EU/mg) and in bulk milligram-to-gram quantities to support assay development, reagent standardization, and larger preclinical campaigns. PSMA (prostate-specific membrane antigen), encoded by FOLH1 and also called glutamate carboxypeptidase II or NAALADase, is a type II transmembrane glycoprotein with a short cytoplasmic tail, a single membrane-spanning region, and a large extracellular enzymatic domain. It functions as a zinc metallopeptidase with folate hydrolase activity in the intestine and N-acetyl-aspartyl-glutamate (NAAG) hydrolase activity in the nervous system. In oncology its relevance stems from strong, largely membrane-restricted overexpression on prostate epithelial cells, which increases with dedifferentiation, androgen independence, and metastatic castration-resistant disease, while normal-tissue expression is comparatively low. PSMA also localizes to the neovasculature of several non-prostate solid tumors. It undergoes constitutive and antibody-induced internalization, a property that makes it attractive for antibody-, ADC-, and radioconjugate-based targeting strategies.

Cell growth-inhibiting gene 27 protein, Folate hydrolase 1, Folylpoly-gamma-glutamate carboxypeptidase, FGCP, Glutamate carboxypeptidase II, GCPII, Membrane glutamate carboxypeptidase, mGCP, N-acetylated-alpha-linked acidic dipeptidase I, NAALADase I, Pro

Detects human PMSA

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.